StockNews.com Upgrades Phibro Animal Health (NASDAQ:PAHC) to “Strong-Buy”

Phibro Animal Health (NASDAQ:PAHC) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Wednesday.

Several other equities research analysts also recently weighed in on PAHC. Barclays raised their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a research report on Tuesday, November 12th. Morgan Stanley lifted their target price on Phibro Animal Health from $20.00 to $25.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $20.50.

Phibro Animal Health Stock Performance

Phibro Animal Health stock opened at $21.98 on Wednesday. The stock’s 50 day moving average is $22.05 and its 200 day moving average is $21.49. The company has a market capitalization of $890.19 million, a P/E ratio of 51.12, a PEG ratio of 0.56 and a beta of 0.53. Phibro Animal Health has a twelve month low of $10.03 and a twelve month high of $25.98. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.12. Phibro Animal Health had a return on equity of 21.59% and a net margin of 1.67%. The firm had revenue of $260.40 million during the quarter, compared to analyst estimates of $277.76 million. During the same quarter in the previous year, the firm earned $0.14 EPS. On average, equities research analysts predict that Phibro Animal Health will post 1.62 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Phibro Animal Health

Several hedge funds and other institutional investors have recently modified their holdings of PAHC. Dimensional Fund Advisors LP increased its position in Phibro Animal Health by 5.7% during the second quarter. Dimensional Fund Advisors LP now owns 775,470 shares of the company’s stock valued at $13,005,000 after acquiring an additional 42,086 shares during the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Phibro Animal Health during the 2nd quarter valued at about $238,000. Public Sector Pension Investment Board lifted its stake in shares of Phibro Animal Health by 6.1% in the 2nd quarter. Public Sector Pension Investment Board now owns 44,796 shares of the company’s stock worth $751,000 after purchasing an additional 2,583 shares during the period. AXA S.A. purchased a new position in shares of Phibro Animal Health in the second quarter worth approximately $906,000. Finally, AQR Capital Management LLC grew its position in Phibro Animal Health by 2.6% during the second quarter. AQR Capital Management LLC now owns 183,210 shares of the company’s stock valued at $3,072,000 after buying an additional 4,700 shares during the period. 99.34% of the stock is owned by institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.